5-Azacytidine for the treatment of myelodysplastic syndromes

Author： Krawczyk Janusz   Keane Niamh   Freeman Ciara Louise   Swords Ronan   O'Dwyer Michael   Giles Francis J  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.9, 2013-06, pp. : 1255-1268

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide for Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

Arsenic trioxide for the treatment of myelodysplastic syndromes

By Vey Norbert  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 613-621

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic spectrum in the treatment of myelodysplastic syndromes

By Hofmann Wolf-K   Baldus Claudia   Uharek Lutz   Thiel Eckhard  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2451-2458

Informa Healthcare

Access to resources Recommend Favorite

The role of azacitidine in the treatment of myelodysplastic syndromes

By Abdulhaq Haifaa   Rossetti James M  

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 12, 2007-12 ,pp. : 1967-1975

Informa Healthcare

Access to resources Recommend Favorite

Novel Biospecific Agents for the Treatment of Myelodysplastic Syndromes

By Gotlib Jason   Greenberg Peter L.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 1, Iss. 4, 2003-11 ,pp. : 473-480

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite